Chromatin conformation capture and dCas9-mediated enhancer blocking studies place the high-risk variant within a prostate cancer–specific enhancer region, serving to modulate expression of MYC, PCAT1, PRNCR1, and other 8q24 genes implicated in prostatic carcinogenesis (30). The gene discussed is MYC; the disease is prostate cancer.